Ratings Healthlead

Equities

End-of-day quote Thailand S.E. Other stock markets 03:30:00 21/06/2024 am IST			5-day change	1st Jan Change
10.4 ^THB	-0.95%		0.00%	0.00%

15/05	Healthlead Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
29/02	Healthlead Public Company Limited Announces Management Changes	CI

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 33.55 times its estimated earnings per share for the ongoing year.
The company is highly valued given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

	1st Jan change	Capi.	ESG Refinitiv
HEALTHLEAD	0.00%	76.96M	-
WALGREENS BOOTS ALLIANCE, INC.	-38.84%	13.78B	B-
JD HEALTH INTERNATIONAL INC.	-40.79%	9.56B	B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-18.63%	7.21B	B
MATSUKIYOCOCOKARA & CO.	-9.73%	5.68B	C+
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+73.68%	4.6B	C
NAHDI MEDICAL COMPANY	-3.80%	4.58B	D-
YIFENG PHARMACY CHAIN CO., LTD.	-18.93%	4.52B	C
CLICKS GROUP LIMITED	+4.63%	4.52B	B
WELCIA HOLDINGS CO., LTD.	-17.13%	2.58B	C-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality